Anebulo Pharmaceuticals posts Q1 net loss

Reuters

Nov 14

Anebulo Pharmaceuticals posts Q1 net loss

Overview

Anebulo fiscal Q1 net loss remains at $2.2 mln, consistent with last year
Operating expenses for fiscal Q1 decreased slightly to $2.3 mln
Company advances selonabant for pediatric cannabis toxicity with NIDA grant support

Outlook

Anebulo expects FDA collaboration for pediatric cannabis toxicity treatment

Result Drivers

NIDA GRANT SUPPORT - Co received $994,300 from NIDA grant to support selonabant study

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		-$0.05
Q1 Net Income		-$2.20 mln
Q1 Basic EPS		-$0.05
Q1 Operating Expenses		$2.30 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release: ID:nBwbS6VKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583951404"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583951404\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583951404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583951404","market":"nz","top_or_hot":-1,"title":"Anebulo Pharmaceuticals posts Q1 net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Anebulo Pharmaceuticals posts Q1 net loss </title></head><body><p><span>Overview</span></p><ul><li><p>Anebulo fiscal Q1 net loss remains at $2.2 mln, consistent with last year</p></li><li><p>Operating expenses for fiscal Q1 decreased slightly to $2.3 mln</p></li><li><p>Company advances selonabant for pediatric cannabis toxicity with NIDA grant support</p></li></ul><p><span>Outlook</span></p><ul><li><p>Anebulo expects FDA collaboration for pediatric cannabis toxicity treatment</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NIDA GRANT SUPPORT - Co received $994,300 from NIDA grant to support selonabant study</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 EPS</p></td><td></td><td><p>-$0.05</p></td><td></td></tr><tr><td><p>Q1 Net Income</p></td><td></td><td><p>-$2.20 mln</p></td><td></td></tr><tr><td><p>Q1 Basic EPS</p></td><td></td><td><p>-$0.05</p></td><td></td></tr><tr><td><p>Q1 Operating Expenses</p></td><td></td><td><p>$2.30 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nBwbS6VKa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anebulo Pharmaceuticals posts Q1 net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnebulo Pharmaceuticals posts Q1 net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Anebulo Pharmaceuticals posts Q1 net loss </title></head><body><p><span>Overview</span></p><ul><li><p>Anebulo fiscal Q1 net loss remains at $2.2 mln, consistent with last year</p></li><li><p>Operating expenses for fiscal Q1 decreased slightly to $2.3 mln</p></li><li><p>Company advances selonabant for pediatric cannabis toxicity with NIDA grant support</p></li></ul><p><span>Outlook</span></p><ul><li><p>Anebulo expects FDA collaboration for pediatric cannabis toxicity treatment</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NIDA GRANT SUPPORT - Co received $994,300 from NIDA grant to support selonabant study</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 EPS</p></td><td></td><td><p>-$0.05</p></td><td></td></tr><tr><td><p>Q1 Net Income</p></td><td></td><td><p>-$2.20 mln</p></td><td></td></tr><tr><td><p>Q1 Basic EPS</p></td><td></td><td><p>-$0.05</p></td><td></td></tr><tr><td><p>Q1 Operating Expenses</p></td><td></td><td><p>$2.30 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nBwbS6VKa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP181:1","article_id":"2583951404","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583951404","pubTimestamp":1763068697,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Anebulo Pharmaceuticals posts Q1 net lossOverviewAnebulo fiscal Q1 net loss remains at $2.2 mln, consistent with last yearOperating expenses for fiscal Q1 decreased slightly to $2.3 mlnCompany advance","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ANEB":"Anebulo Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Anebulo Pharmaceuticals第一季度净亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANEB":0.9},"content_text":"Anebulo Pharmaceuticals posts Q1 net loss OverviewAnebulo fiscal Q1 net loss remains at $2.2 mln, consistent with last yearOperating expenses for fiscal Q1 decreased slightly to $2.3 mlnCompany advances selonabant for pediatric cannabis toxicity with NIDA grant supportOutlookAnebulo expects FDA collaboration for pediatric cannabis toxicity treatmentResult DriversNIDA GRANT SUPPORT - Co received $994,300 from NIDA grant to support selonabant studyKey DetailsMetricBeat/MissActualConsensus EstimateQ1 EPS-$0.05Q1 Net Income-$2.20 mlnQ1 Basic EPS-$0.05Q1 Operating Expenses$2.30 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Press Release: ID:nBwbS6VKaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}